Chemotherapy improves low performance status lung cancer patients

Area of Science:

• Oncology
• Clinical Medicine
• Cancer Research

Background:

• Advanced non-small cell lung cancer (NSCLC) often presents with poor performance status (PS), complicating treatment decisions.
• Patients with poor PS (Karnofsky score 60-70) historically have limited treatment options and poorer prognoses.

Purpose of the Study:

• To evaluate the efficacy and clinical benefit of cisplatin-based combination chemotherapy in advanced NSCLC patients with poor performance status.
• To assess response rates, clinical improvement, and survival outcomes in this patient subgroup.

Main Methods:

• Retrospective analysis of a randomized trial involving 485 advanced NSCLC patients.
• Patients received three courses of induction chemotherapy: gemcitabine, ifosfamide, and cisplatin.
• Performance status (PS) was assessed using the Karnofsky scale; 80% had good PS (80-100), 20% had poor PS (60-70).

Main Results:

• Overall response rates were 38% for good PS and 28% for poor PS patients.
• Clinical improvement (achieving good PS) was observed in 25% of poor PS patients.
• Poor PS patients experienced significantly worse survival, but responders had similar survival regardless of initial PS. Toxic deaths were higher in the poor PS group (9.2% vs 2.1%).

Conclusions:

• Combination chemotherapy demonstrates potential clinical benefit for advanced NSCLC patients with poor performance status.
• Treatment can lead to performance status improvement and comparable survival among responders, despite increased toxicity risks.
• These findings support considering combination chemotherapy for selected advanced NSCLC patients with poor PS.